Aphria Inc (NYSE:APHA) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Aphria Inc (NYSE:APHA) have earned an average rating of “Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $11.51.

Several brokerages have commented on APHA. ValuEngine upgraded shares of Aphria from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. CIBC reiterated a “sell” rating and issued a $6.50 price target on shares of Aphria in a research report on Wednesday. Zacks Investment Research upgraded shares of Aphria from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research report on Thursday. Pi Financial set a $9.00 price target on shares of Aphria and gave the stock a “buy” rating in a research report on Tuesday. Finally, Jefferies Financial Group set a $8.30 price target on shares of Aphria and gave the stock a “buy” rating in a research report on Tuesday.

Shares of NYSE APHA opened at $4.75 on Friday. The firm’s 50-day simple moving average is $5.85 and its 200 day simple moving average is $6.80. Aphria has a fifty-two week low of $3.75 and a fifty-two week high of $15.41. The stock has a market cap of $1.37 billion, a P/E ratio of -43.18 and a beta of 2.85.

Aphria (NYSE:APHA) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.10. The business had revenue of $126.10 million during the quarter, compared to the consensus estimate of $131.15 million. The company’s revenue was up 848.1% compared to the same quarter last year. Analysts expect that Aphria will post 0.02 EPS for the current year.

A number of institutional investors have recently modified their holdings of the business. ETF Managers Group LLC bought a new stake in Aphria in the second quarter worth about $48,941,000. Vanguard Group Inc. increased its stake in Aphria by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 5,402,302 shares of the company’s stock worth $37,870,000 after purchasing an additional 135,714 shares in the last quarter. Bank of America Corp DE increased its stake in Aphria by 410.2% in the 2nd quarter. Bank of America Corp DE now owns 507,034 shares of the company’s stock worth $3,554,000 after purchasing an additional 407,658 shares in the last quarter. Swiss National Bank increased its stake in Aphria by 8.0% in the 2nd quarter. Swiss National Bank now owns 445,400 shares of the company’s stock worth $3,132,000 after purchasing an additional 33,000 shares in the last quarter. Finally, Jefferies Group LLC increased its stake in Aphria by 449.7% in the 2nd quarter. Jefferies Group LLC now owns 323,900 shares of the company’s stock worth $2,273,000 after purchasing an additional 416,516 shares in the last quarter. Hedge funds and other institutional investors own 10.94% of the company’s stock.

About Aphria

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Recommended Story: What is a death cross?

Analyst Recommendations for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.